Prostate Cancer

Midwest CEPAC
September 13, 2018 9am-5pm CT

Chicago Marriott at Medical District/UIC

625 S Ashland Ave

Chicago, IL 60607

The Midwest CEPAC deliberated and voted on evidence presented in ICER's report on anti-androgen drugs for high risk prostate cancer. During this meeting, the Council also discussed ICER's review of treatments for amyloidosis.

Key Dates

Associated Materials

02/16/2018 – 03/07/2018

03/12/2018

Open to public comment until April 2, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.


03/12/2018

03/12/2018 – 04/02/2018

04/09/2018

04/25/2018

05/31/2018

07/12/2018

Open to public comment until August 9, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.